Skip Navigation LinksHome > October 2013 - Volume 19 - Issue 11 > Serum M 30 Levels Reflects Ulcerative Colitis Activity
Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e3182a0ea38
Original Clinical Articles

Serum M 30 Levels Reflects Ulcerative Colitis Activity

Aktaş, Bora MD*; Altinbaş, Akif MD*; Başar, Ömer MD*,†; Yilmaz, Bariş MD*; Ekiz, Fuat MD*; Giniş, Zeynep MD; Öztürk, Gülfer MD; Çoban, Şahin MD*; Tuna, Yaşar MD; Uçar, Engin MD*; Erarslan, Elife*; Yüksel, Osman MD*

Collapse Box

Abstract

Background:

Apoptosis plays a role in epithelial and mucosal injury, which is 1 of the mechanisms in the pathogenesis of ulcerative colitis. Apoptotic cells increase as a result of injured mucosa in ulcerative colitis and serum M 30 levels increase in epithelial cell apoptosis. In this study, we aimed to evaluate the relation between M 30 serum levels and ulcerative colitis activity.

Methods:

Eighty patients with ulcerative colitis and 40 healthy controls were enrolled into the study. The patient group consisted of 31 extensive colitis, 30 left-sided colitis, and 19 proctitis. The activity of ulcerative colitis was determined with clinical and endoscopic findings. Serum M 30 levels, acute phase reactants, and biochemical tests were analyzed in all subjects.

Results:

Serum M 30 levels in patients with active ulcerative colitis were significantly higher when compared with the healthy controls (165.6 ± 60.6 and 129.6 ± 37.4; P = 0.003). Serum M 30 levels in active left-sided colitis patients was significantly higher when compared with patients in remission phase (180.6 ± 58.5, 141.5 ± 35.4; P = 0.044). When we exclude patients with ulcerative proctitis, M 30 levels in active ulcerative colitis patients were significantly higher than that the patients in remission phase (174.0 ± 63.5, 135.0 ± 29.9; P = 0.017).

Conclusions:

We found that M 30 levels increase in patients with active ulcerative colitis. Our findings support the role of apoptosis demonstrated by serum M 30 levels in the pathogenesis of active ulcerative colitis.

Copyright © 2013 Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.